



**QUEEN'S
UNIVERSITY
BELFAST**

Catalytic ferromagnetic gold nanoparticle immunoassay for the detection and differentiation of *Mycobacterium tuberculosis* and *Mycobacterium bovis*

Gilbride, B., Schmidt Garcia Moreira, G. M., Hust, M., Cao, C., & Stewart, L. (2021). Catalytic ferromagnetic gold nanoparticle immunoassay for the detection and differentiation of *Mycobacterium tuberculosis* and *Mycobacterium bovis*. *Analytica Chimica Acta*, 1184, Article 339037. <https://doi.org/10.1016/j.aca.2021.339037>

Published in:
Analytica Chimica Acta

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2021 Elsevier.

This manuscript is distributed under a Creative Commons Attribution-NonCommercial-NoDerivs License

(<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>

1. Introduction

Over recent decades, nanomaterials have emerged as promising tools for use in disease diagnosis [1]. In particular, gold nanoparticles (AuNPs)¹ hold great potential in biosensing applications because of their ease of functionalisation, high surface-area-to-volume ratio, unique bio-catalytic abilities, and high stability. AuNPs are employed in a wide range of biomedical applications including drug-delivery, bio imaging and as optical indicators in lateral flow assays, whilst their intrinsic peroxidase-like activity has facilitated their use in enzyme-like mediated biocatalysis of common ELISA substrates including 3,3',5',5'-tetramethylbenzidine (TMB) [2]. Similarly, magnetic nanoparticles (MNPs) which can be manipulated and controlled by magnetic fields have been used as catalysts in bioimaging and biomedicine [3]. MNPs can have dual functionality: their magnetic properties facilitate bio-separation of target antigens; and they can biocatalyse due to the surface charge associated catalytic activity conferred by their external surface shell [4]. Combining two different nanomaterials in a composite NP structure has led to the development of bi-functional NPs including metallic magnetic iron oxide core – gold shell NPs which are capable of magnetic separation and are biocompatible [5-7].

Tuberculosis (TB) is a disease caused by a group of organisms collectively called the *Mycobacterium tuberculosis* complex (MTBC). Over one-quarter of the world's population is infected with MTBC organisms and TB is the leading cause of death worldwide from a single infectious agent [8]. *Mycobacterium tuberculosis* (MTB) is the primary cause of human tuberculosis (HTB), however, *Mycobacterium bovis* can also cause TB in humans, referred to as zoonotic TB (ZTB) [9]. TB disease caused by *M. bovis* is clinically and pathologically indistinguishable from TB caused by MTB. In addition, both mycobacteria stain as acid fast

¹ Abbreviations: MTBC, *Mycobacterium tuberculosis* complex; Au-Fe₃O₄ NPs, Ferromagnetic gold nanoparticles; Fe₃O₄ NPs, iron oxide nanoparticles; TMB, 3,3',5',5'-tetramethylbenzidine; oxTMB, 3,3',5,5'-tetramethylbenzidine diamine; PBS, Phosphate-buffered saline; NPIDA, nanoparticle based immune detection assay; MTB, *Mycobacterium tuberculosis*; mAb, monoclonal antibody; AuNPs, gold nanoparticles; MNPs, magnetic nanoparticles; ZTB, zoonotic TB; HTB, human tuberculosis; CDC, Centers for Disease Control and Prevention; WHO, World Health Organisation; NAATs, nucleic acid amplification tests; HRP, Horseradish peroxidase; QUBPA-1, MTBC selective polyclonal antibody; QUBMA-1, *M. bovis* selective monoclonal antibody

24 bacilli, are 99.95% similar at the genome level, and have identical 16S rRNA sequences [10].
25 Differentiation between them is crucial as *M. bovis* is intrinsically resistant to pyrazinamide,
26 one of the routinely used front-line anti-TB drugs [11]. In high TB burden, low-income
27 countries, speciation of the causative organisms is rarely undertaken, with the result that when
28 TB is diagnosed it is assumed to be caused by MTB [12]. Inaccurate diagnosis of ZTB
29 compromises the efficacy of the treatment regime. This increases the risk of disease
30 transmission and potentially contributes to the development of antibiotic-resistant TB, resulting
31 in increased patient morbidities and mortalities [13]. Differential diagnosis of the causative
32 agent of TB infection is therefore a crucial part of effective disease control plans to: (i)
33 effectively direct chemotherapy; (ii) facilitate the study of the transmission of mycobacteria
34 between humans and animals; and (iii) provide more accurate estimations of the scale of ZTB.
35 The “WHO End TB Strategy” details targets, including an 80% reduction in TB incidence and
36 95% decrease in TB mortality by 2030, by prioritising patient-centred care strategies,
37 expanding access to TB treatments for all patients, and calling for diagnosis and treatment of
38 every person with TB, including ZTB [14]. Therefore, the development of more rapid and easy-
39 to-use testing approaches for TB detection and speciation are necessary.

40 The gold standard for TB diagnosis is the isolation of MTB by culture, but this is expensive
41 and time-consuming because of the slow-growing nature of MTBC organisms, which can take
42 weeks for colonies to grow [15]. In low-income countries, TB diagnosis relies mainly on the
43 detection of acid-fast bacilli using sputum smear microscopy, but this method is non-specific
44 and has low sensitivity [16]. Molecular diagnostic assays including Nucleic Acid Amplification
45 Tests (NAATs) [17], and the WHO endorsed GeneXpert MTB/RIF [18], ELISA [19] and other
46 immunological tests such as the T-SPOT and QuantiFERON TB IFN- γ release assays [20]
47 offer more sensitive diagnosis than conventional sputum smear microscopy, but suffer from
48 limitations including requirements for highly skilled personnel, expensive lab equipment and
49 complex experimental procedures. In addition, none of these tests can differentiate between
50 MTB and *M. bovis*.

51 The slow-growing pathogenic mycobacteria use a variety of strategies thought to influence
52 immunopathogenicity. The most important of these tools are secreted proteins, such as the 6-
53 kDa early secreted antigenic target (ESAT6) [21], the 10-kDa culture filtrate protein (CFP10)
54 [22], the antigen 85 (Ag85) complex which has a significant role in the virulence of MTB [23],
55 and MPT64, which is a secreted protein involved in inhibition of macrophage apoptosis [24].
56 Detection of these proteins can be used to differentiate MTBC from the non-TB producing
57 mycobacteria, for example, the detection of the MPT64 antigen has been used in various
58 assays such as the SD Bioline [25], Becton Dickinson MGIT TBc ID test [26] and Tauns Capilia
59 TB-Neo [27]. These diagnostic tests will identify MTBC, but will not speciate *M. bovis*.
60 Differentiation of MTB and *M. bovis* has been demonstrated using molecular based methods
61 which target the *gyrB* (Rv0005) [28] and *hupB* (Rv2986c) [29] gene loci. The former is a two-
62 step approach using an AuNP-based colorimetric nanoprobe assay for the rapid detection of
63 MTB complex, and differentiation of *M. bovis* and MTB using *gyrB* (Rv0005) target [28]. On
64 the other hand, Prabhakar *et al* reported a PCR based assay for distinguishing MTB and *M.*
65 *bovis* by targeting the *hupB* gene in a single reaction [29]. Three primers—N, M, and S—were
66 designed and the primer pair N-S amplified the entire *hupB* gene. The C-terminal part of the
67 gene was selectively amplified by using primers M and S and the size differences in PCR
68 products were observed to be reliable for distinguishing MTB and *M. bovis* from other MTBC
69 members. In a previous study, focused in the veterinary context where *M. bovis* predominates,
70 an *M. bovis* cell wall-associated protein was used to develop a lateral flow device capable of
71 detecting *M. bovis* [30, 31]. For translation into the human diagnostic context, where both MTB
72 and *M. bovis* are encountered, a dual test is required that can both identify MTBC and
73 differentiate *M. bovis*. In this study we produced a novel recombinant antibody to MPT64 and
74 combined this with previously produced antibodies to develop a low-cost, portable and highly
75 sensitive NP based assay. The combination of antibodies used resulted in an immunoassay
76 which could both detect MTBC and differentiate *M. bovis*. This novel assay, when compared
77 with conventional ELISA using the same antibodies, was found to achieve greater
78 physiochemical stability, catalytic efficiency, and a shorter time to detection of MTBC

organisms. The magnetic capabilities of the functionalised Au-Fe₃O₄ NP bioconjugates were exploited during sample preparation, and their intrinsic peroxidase-like catalytic activity resulted in a semi-quantitative colorimetric detection methodology which directly confirms presence/absence of MTBC organisms. The developed assay enabled simultaneous immunological sensing and differentiation of *M. bovis* and MTB. No cross-reactivity was detected with other non-tuberculosis *Mycobacterium spp.* tested. This novel immunoassay combined sample preparation and target detection, reduced the number of steps, and therefore the time required to detection, when compared to traditional ELISA technique.

2. Methods

2.1 Materials

TMB was purchased from Merck-Millipore, hydrogen peroxide (H₂O₂), sodium acetate (Na Ac), sodium bicarbonate, Tween 20, horseradish Peroxidase (HRP), phosphate-buffered saline (PBS), sulphuric acid (H₂SO₄), dithiothreitol (DTT), Fe (II) and Fe (III) chloride, tetramethylammonium hydroxide (TMOH), sodium citrate (Na₃C₆H₅O₇) and tetrachloroauric acid trihydrate (HAuCl₄ · 3H₂O) were purchased from Sigma-Aldrich. MPT64 antigen was purchased from 2BScientific Ltd (Heyford, Oxfordshire, UK). Costar high-binding 96-well plates were purchased from Corning (New York, USA), 96-well polypropylene microtiter plates were purchased from Greiner Bio-One (Kremsmünster, Austria), DAKO Goat anti-rabbit and anti-mouse HRP-conjugated antibodies were purchased from Agilent (CA, USA). Middlebrook 7H9 broth was purchased from Becton Dickinson DIFCO (USA). PD-10 columns were purchased from GE-Healthcare. MTB H37Rv, *M. bovis* AF2122/97, *M. kansasii* NCTC10268, *M. avium* subsp. *paratuberculosis* NCTC8578 and *M. bovis* (BCG-strain) NCTC5692 cell suspensions were produced in-house as detailed previously [30]. Briefly, enumerated bacterial cultures were centrifuged and washed three times in sterile PBS (0.1M, pH 7.4) before resuspension in PBS. All mycobacterial cell suspensions were subjected to a 10 kGy dose of gamma radiation (Gammabeam 650 cobalt irradiator, AFBI, Belfast). After radiation treatment, samples of each suspension were cultured on Middlebrook 7H10 agar and plates read after

56 days, to ensure complete inactivation of all pathogenic mycobacteria before use. Irradiated bacterial stock cultures diluted in PBS (10^6 CFU mL⁻¹) were stored at -80 °C until required. *Escherichia coli* TG1 DSM6056, and XL1-Blue MRF' strains were cultivated in house.

2.2 Antibody production

An *M. bovis* mAb and MTBC polyclonal antibodies, labelled QUBMA-1 and QUBPA-1 respectively were sourced from a previous study [32].

2.2.1 Recombinant antibody selection via phage display

Recombinant antibodies against MPT64 were generated by antibody phage display. The antibody selection was performed as described previously with modifications and the resultant monoclonal binders were sequenced and analysed using VBASE2 (www.vbase2.org) [33-35]. (See S1)

2.2.2 Initial characterisation

Unique single-chain variable fragment (scFv) sequences isolated by antibody-phage display in Costar high-binding 96-well plates were subcloned into pCSE2.6-mIgG2a-Fc-XP [36] using *NcoI/NotI* (New England Biolabs, Frankfurt, Germany). For production, the transfected EXPI293F cells were cultured in chemically defined medium F17 (Thermo Fisher Scientific) supplemented with 0.1% pluronic F68 (PAN-Biotech, Aidenbach, Germany) and 7.5 mM L-glutamine (Merck). A subsequent protein A purification was performed as described previously [37].

The purified scFv-Fc antibodies were initially characterised by indirect ELISA, performed by coating 50 ng per well of MPT64 diluted in PBS. The recombinant antibodies were 10-fold serially diluted in 2% Modified PBS-T (2% (w/v) milk powder in PBS; 0.05% Tween20) (MPBS-T) from 10 µg mL⁻¹ to 3.16 ng mL⁻¹, and 100 µL per well of each dilution added. The secondary antibody, goat anti-mouse HRP, was added and the reaction developed with TMB solution and read at 450 nm with a 620 nm reference. As a negative control, a non-related His-tagged

recombinant protein produced in *E. coli* was coated on a plate and tested in the same way. Absorbance values were used to calculate EC₅₀ value using GraphPad software (Prism, v 5.01).

2.3 Synthesis of Fe₃O₄ and Au-Fe₃O₄ composite NPs

The method of Pham *et al* was used to synthesise Fe₃O₄ NPs [38]. Briefly, ddH₂O (20 mL) was degassed by sonicating for 30 min in a triple neck flask before purging with N₂ gas for 20 min. Fe (III) chloride (4.6g) and Fe (II) chloride (1.7g) were added to HCl (100 mM) and stirred vigorously until fully dissolved before adding NaOH (2 M, 20 mL) dropwise yielding a dark black magnetic precipitate. The precipitate was collected using a 3,000 G magnet and washed in ddH₂O before resuspension in tetramethylammonium hydroxide (TMOH) (0.1 M, 10 mL). Iron oxide NPs were obtained by further washing and dissolving in nitric acid (HNO₃) (0.01 M, 10 mL) with stirring until the solution produced a brown colour. The synthesised iron oxide NPs were washed in ddH₂O before resuspending in TMOH (0.1 M, 10 mL).

A modified version of the Turkevich method for AuNP production in trisodium citrate [39] was used to synthesise gold-iron oxide nanocomposites. Sodium citrate (0.1 M, 10 mL) and synthesised iron oxide NPs (1 mL) were boiled with stirring for 10 min, before addition of HAuCl₄·4H₂O (1 mM, 1 mL) to produce iron oxide-gold composite NPs. A red-wine colour developed within 10 min and the resultant composite NPs were magnetically collected and washed three times in ddH₂O (10 mL), and once in sodium citrate (0.1 M, 10 mL), before storing at 4 °C until use. The resultant composite NPs were standardised to OD₅₅₀ = 1.0 before use.

2.4 Characterisation of Au-Fe₃O₄ NPs

The peroxidase activity of the Au-Fe₃O₄ NPs was assessed at a range of H₂O₂ concentrations, pH and temperatures. Au-Fe₃O₄ NPs (0.1 nM, OD₅₅₀ = 1) and HRP (3 nM) solutions were prepared in sodium acetate buffer (2 mM, pH 5, 1 mL). The peroxidase activity of Au-Fe₃O₄ NPs and HRP was compared by incubating 1 mL of each Au-Fe₃O₄ NP solution and HRP in

sodium acetate buffer with TMB (0.65 mM, 100 μ L) for 2 hrs at 37 $^{\circ}$ C. The peroxidase activity was measured at a range of: (i) H_2O_2 concentrations, by preparing solutions of Au- Fe_3O_4 NP (1 mL) at final H_2O_2 concentrations of 0, 1, 2, 3, 4, 6, 8 and 10% (v/v), (ii) pH, by preparation of Au- Fe_3O_4 NP solutions (1 mL) with pH adjusted to 2, 3, 4, 5, 6, 7, 8 and 9 and, (iii) temperatures, by varying the incubation temperature of five Au- Fe_3O_4 NP solutions (1 mL) to 20, 30, 40, 55 and 65 $^{\circ}$ C. TMB substrate oxidation absorbance readings were measured using a Safire 96-well ELISA plate reader (Tecan, Switzerland) at 370 nm immediately after incubation.

TMB oxidation was demonstrated by preparing two solutions of 0.65 mM TMB / 8% (v/v) H_2O_2 in sodium acetate buffer (2 mM, pH 5, 1 mL) in semi-micro cuvettes. Au- Fe_3O_4 NPs (0.1 nM, 10 μ L) were added to one cuvette and the TMB substrate oxidation profile recorded in both cuvettes using a spectrophotometer.

To determine if the relative peroxidase activity being measured was due to intact Au- Fe_3O_4 NPs, two solutions of Au- Fe_3O_4 NPs (0.1 nM) in sodium acetate buffer (2 mM, pH 5, 1 mL) were prepared. A 3000 G permanent magnet was used to remove the Au- Fe_3O_4 NPs from one solution. One hundred μ L of 0.65 mM TMB / 8% (v/v) H_2O_2 was added to both and the relative peroxidase activity of each solution was measured continuously for 10 min at 370 nm using a spectrophotometer.

2.5 Characterisation of NP structure

Transmission electron microscopy images of Au- Fe_3O_4 , Au and Fe_3O_4 NPs were obtained using a Joel JEM-1400 Plus Transmission Electron Microscope 120 kV. Samples were prepared on carbon-nickel grids in 50% (v/v) ethanol. UV-Vis analysis of particles was achieved using a Cary 60 spectrophotometer (Agilent Technologies, USA). Dynamic Light Scattering (DLS) particle size and zeta potential measurements were obtained using a Malvern Zetasizer Nano ZS (Malvern Panalytical, Worcestershire, UK)

2.6 Au- Fe_3O_4 NP functionalisation and characterisation

191 QUBPA-1 was used as the capture antibody in the assay. Au-Fe₃O₄ NPs were bio-
192 functionalised by direct coupling of QUBPA-1 using DTT [40-42]. Briefly, DTT (0.35 mg) was
193 added per 1 mL of antibody (0.2 mg mL⁻¹) diluted in PBS EDTA (2 mM, pH 7.4, 1 mL) buffer
194 solution, and incubated on a rotator for 30 min at room temperature. Excess reactants were
195 removed by separation in PD-10 columns using PBS EDTA washing buffer before collecting
196 eight successive eluted antibody fractions (0.5 mL). Antibody fraction concentrations were
197 measured at 280 nm on a NanoDrop 8000 (Thermoscientific, UK) and the peak antibody
198 fraction (0.1 mg mL⁻¹) was added to 1 mL of Au-Fe₃O₄ NPs (OD₅₅₀ = 1) and left for 16 h at
199 room temperature to enable conjugation. Resultant antibody Au-Fe₃O₄ NP bioconjugates were
200 washed three times in PBS-0.05% Tween-20 buffer (pH 7.4) (PBS-T) and stored at 2 – 8 °C.
201 Relative peroxidase activity of uncoated and antibody functionalised Au-Fe₃O₄ NPs was
202 determined by preparing solutions of uncoated Au-Fe₃O₄ NPs and antibody functionalised Au-
203 Fe₃O₄ NPs (0.1 nM) in sodium acetate buffer (2 mM, pH 5, 1 mL). TMB (0.65 mM) / 8% (v/v)
204 H₂O₂ (100 µL) was added to each sample and the relative peroxidase activity of each solution
205 measured continuously for 10 min at 370 nm using a spectrophotometer.

206

207 **2.7 Immunoassays**

208 **2.7.1 NP-based Immune Detection Assay (NPIDA)**

209 Nunc Maxisorp™ plates were coated with detector antibodies, either recombinant antibody or
210 QUBMA-1 (10 µg mL⁻¹, 100 µL), diluted in bicarbonate buffer (0.1 M, pH 9.4), and incubated
211 for 16 h at 4 °C. After incubation, they were washed five times with PBS-T wash buffer before
212 blocking with assay buffer (PBS-T/BSA (1% w/v)), (200 µL per well) for 2 h at 37 °C with
213 shaking. The solution was then discarded.

214 Concurrently, Au-Fe₃O₄ NP-antibody bioconjugates (100 µL), coated with the capture
215 antibody, were incubated with whole cells of either MTB or *M. bovis* (1 x 10⁵ CFU mL⁻¹) diluted
216 in assay buffer (1 mL) for 16 h at 37 °C in 1.5 mL tubes. Negative control samples were
217 prepared by incubating Au-Fe₃O₄ NP-antibody bioconjugates (100 µL) with assay buffer only.
218 After incubation with target cells, Au-Fe₃O₄ NP-antibody bioconjugates were washed three

times in PBS-T/SDS (0.001 % w/v), collected using a magnetic stand between each wash. The washed bioconjugate was then added to the antibody coated, blocked plate, and incubated for 2 h at 37 °C with shaking. The plates were washed five times using PBS-T before adding TMB substrate (100 µL per well). The colour was left to develop for 30 min, stop solution (2.5 M H₂SO₄, 25 µL per well) added, and the plate read at 450 nm using a microplate reader.

2.7.2 Conventional sandwich ELISA

For comparison with conventional sandwich ELISA the same method was followed as detailed previously for the NPIDA with minor changes. Nunc Maxisorp™ plates were coated as before. After removing blocking buffer and washing plates five times with PBS-T, each target bacterial culture (1 x 10⁵ CFU mL⁻¹, 100 µL per well) diluted in assay buffer, was added directly to the wells and incubated for 2 h at 37 °C with shaking. Plates were washed five times with PBS-T, the detector antibody (either QUBPA-1, GSM237-G8 or QUBMA-1) (10 µg mL⁻¹, 100 µL per well) added, and the plates incubated for 1.5 h at 37 °C. Plates were washed five times with PBS-T and the appropriate secondary antibody, (DAKO anti-mouse/ rabbit HRP conjugate antibody) (0.25 µg mL⁻¹, 100 µL per well), diluted in assay buffer added, and incubated for 1 h at 37 °C with shaking. Plates were then washed 5 times in PBS-T before adding TMB substrate (100 µL per well). The plate was left for 30 mins before adding stop solution, (2.5 M H₂SO₄, 25 µL per well) and the absorbance read at 450 nm using a microplate reader.

2.7.3 Limits of Detection of developed assays

The 50% limit of detection (LOD_{50%}) for both the NPIDA and the conventional sandwich ELISA were determined both in assay buffer and in BACTEC™ MGIT™ TB media (7H9 Middlebrook broth/10 % OADC) using the assay procedures detailed above. A tenfold dilution series containing 10⁵, 10⁴, 10³, 10², 10¹ and 0 CFU mL⁻¹ of both MTB and *M. bovis* whole cells was prepared in assay buffer and in BACTEC™ MGIT™ TB media. In the NPIDA, each cell dilution (1 mL) was incubated with Au-Fe₃O₄ NP-antibody bioconjugates, whereas in the conventional

sandwich ELISA each cell dilution was added to a previously coated 96-well plate (recombinant antibody or QUBMA-1) after the blocking step. All samples were prepared in triplicate, all experiments were repeated three times resulting in a total of 9 replicate values at 6 dilutions. The LOD_{50%} was determined using the generalized Spearman-Kärber LOD_{50%} calculation for 6-level spiking protocols [43].

3. Results and Discussion

In this study, a novel ferromagnetic gold NP immunoassay was developed and evaluated for the detection and differentiation of MTB and *M. bovis*, the main causative agents of TB in humans. A unique recombinant monoclonal antibody to a key MTBC protein was generated and used in conjunction with a panel of pre-existing antibodies to cell surface and secreted antigens of MTB and *M. bovis*, to develop the assay. Au-Fe₃O₄ NP bioconjugates were prepared by direct coupling of antibodies to Au-Fe₃O₄ NPs which were then used to develop the NPIDA. The NPIDA was capable of sensitive detection and differentiation of MTB and *M. bovis* cells.

3.1 Au-Fe₃O₄ NP composition and peroxidase-like activity

Fe₃O₄ NPs were synthesised first, and subsequently alloyed with Au to form Au-Fe₃O₄ NPs following a modified version of the established sodium citrate seeding method by Brown *et al* [44]. As seen in **Figure 1a**, Fe₃O₄ NPs do not exhibit any peaks from 400-800 nm (green line), and AuNPs possess a characteristic plasmonic peak at 517 nm (solid line). The formation of Au-Fe₃O₄ NPs was confirmed by the UV-Vis spectroscopy with the presence of a distinct peak at 550 nm corresponding to the surface plasmonic peak of the Au nanomaterial. The shift in peak wavelength (from 517 to 550 nm) corresponded to an increase in NP diameter. This has previously been observed during Au-Fe₃O₄ NP synthesis, wherein successful assembly of Au with the Fe₃O₄ NPs led to a similar shift in peak wavelength [45]. The magnetic capabilities of Fe₃O₄ NPs and Au-Fe₃O₄ NPs were demonstrated by collection using a 3000 G permanent magnet, resulting in a phase separation in both the Fe₃O₄ NP and Au-Fe₃O₄ NP solutions after

the ferromagnetic NPs had migrated towards the permanent magnet (**Figure 1b**). The demonstration of both magnetism and plasmonic properties unambiguously confirms the successful production of Au-Fe₃O₄ NPs. TEM images further revealed that the multiple-faced Fe₃O₄ NPs and the Au-Fe₃O₄ NPs composites have estimated diameters ranging from 15 – 50 nm (**Figure 1c**). Pham *et al* also reported similar observations during Au-Fe₃O₄ NP synthesis, noting the formation of spherical-like, multiple-faced Au-Fe oxide NPs following the reduction of Au³⁺ ions onto ‘jagged’ Fe oxide NPs [38]. DLS measurements were taken for Fe₃O₄ NPs and Au-Fe₃O₄ NPs in liquid phase and revealed larger nanoparticle hydrodynamic diameters, i.e. 153.7 and 300.6 nm, respectively (**Figure S1a**). The discrepancy between the estimated diameters obtained by TEM and by DLS is thought to be as a result of the magnetic nature of the iron oxide component of the nanomaterials which causes them to magnetise and agglomerate into larger particle clusters, an effect which has also been reported by other groups during analysis of Au-Fe₃O₄ NPs [46, 47]. In fact, the hydrodynamic diameter of the same Au-Fe₃O₄ NPs increased from ca. 300 nm to 800 nm as a function of time (**Fig S1b**) due to the magnetised susceptibility of the Au-Fe₃O₄ NPs. The agglomeration causing apparent increased particle size (**Fig S1c**) can be reversed by applying a prompt sonication (data not shown).

3.2 Functionalisation of the Au-Fe₃O₄ NPs forms the basis of a novel NP-based immunoassay

The intrinsic peroxidase-mimicking ability of Au-Fe₃O₄ NPs enables them to perform as an artificial-HRP nanozyme capable of oxidising TMB in the presence of H₂O₂. The catalytic efficiency of enzyme catalysts such as HRP and inorganic nanozymes, like Au-Fe₃O₄ NPs, is dependent on environmental conditions including temperature, pH and H₂O₂ concentration. Inorganic nanomaterials, such as Au-Fe₃O₄ NPs, are predicted to have greater thermal, pH and chemical tolerances than organic enzymes like HRP [48]. To assess this hypothesis, consecutive experiments were set up, measuring TMB oxidation at fixed concentrations of 3 nM HRP and 0.1 nM Au-Fe₃O₄ NP respectively, under varying environmental conditions

303 including H_2O_2 concentration, temperature and pH. Au- Fe_3O_4 NPs were found to require H_2O_2
 304 concentrations of 8 % (v/v) to achieve maximal activity and were inhibited at lower/ higher
 305 concentrations, whereas, for HRP the optimal H_2O_2 concentration was determined to be 0.5
 306 % (v/v) which decreased rapidly at increasing concentrations (**Figure 2a**). Both Au- Fe_3O_4 NP
 307 and HRP exhibited optimal catalytic activity around pH 5, however the Au- Fe_3O_4 NPs
 308 demonstrated greater peroxidase activity over a broader range of pH values, pH 4 to pH 7,
 309 compared to HRP (**Figure 2b**). At temperatures over 37 °C, HRP catalytic activity was 25%
 310 lower than Au- Fe_3O_4 NPs (**Figure 2c**). The maximum point of each curve was set as 100%
 311 relative activity and optimal conditions for TMB oxidation were determined to be 8% H_2O_2 , 37
 312 °C at pH 5. The oxidation of TMB (0.65 mM) by Au- Fe_3O_4 NPs in the presence of 8% H_2O_2
 313 produces a blue oxidation product, whilst in the absence of Au- Fe_3O_4 NPs, TMB is unoxidised
 314 and the solution remains colourless (**Figure 2d**). TMB oxidation produces two major peaks
 315 observed at 370 nm and 652 nm by Au- Fe_3O_4 NPs corresponding to the formation of blue,
 316 oxidised TMB product (**Figure 2e**) [49]. Previous studies have highlighted the peroxidase-like
 317 activity of leached Fe (II) and Fe (III) ions in acidic solution [7, 48]. Therefore, to confirm that
 318 the observed peroxidase-like activity is due to intact Au- Fe_3O_4 NPs, and not leached iron ions,
 319 a 3000G magnet was used to remove Au- Fe_3O_4 NPs and the remaining solution analysed
 320 along with the original preparation of Au- Fe_3O_4 NPs. TMB was added to each sample and
 321 relative peroxidase activity of both solutions measured at 370 nm for 10 min. In the presence
 322 of Au- Fe_3O_4 NPs, TMB oxidation increased steadily over 10 min, producing the blue coloured
 323 oxidised TMB product, whereas in samples with Au- Fe_3O_4 NPs removed (No-NP), TMB
 324 remained unoxidised and the sample remained colourless (**Figure 2f**). The peroxidase-like
 325 activity was therefore due to intact Au- Fe_3O_4 NPs which represent potential candidates for
 326 oxidation of TMB in environmental conditions unsuitable for conventional organic enzymes
 327 like HRP.
 328 Modification of NPs with small ligands and metal ions has often been reported to result in a
 329 decrease of catalytic activity. For example, Tao *et al* [50], reported a decrease in peroxidase-
 330 like activity of AuNPs as a result of hindrance by the small ligand biomolecule dopamine.

Likewise, antibodies may cause a decrease in peroxidase activity by surface hindrance. In this study, we compared the relative peroxidase activity of uncoated and antibody-functionalised Au-Fe₃O₄ NPs (OD₅₅₀ = 1) (**Figure 3**). After 10 mins the rate of formation of blue oxidised TMB product was reduced by approximately 25 % following surface attachment of the antibody to the Au-Fe₃O₄NPs (uncoated Au-Fe₃O₄ NPs Abs = 1.04 OD₃₇₀, antibody-functionalised Au-Fe₃O₄ NP Abs = 0.72 OD₃₇₀) (**Figure 3a**). However, despite this suppression of catalytic activity the resultant bioconjugate could still be used for direct sample sensing. The UV-Vis spectral analysis for TMB oxidation showed a decrease in peak absorbance at 370 nm and 652 nm, corresponding to the suppression of TMB oxidation by the antibody functionalised Au-Fe₃O₄ NPs (**Figure 3b**).

Having characterised the activity of the individual constituents they were then combined with antibodies to develop the NPIDA. In the first step the antibody-functionalised Au-Fe₃O₄ NP bioconjugate was incubated with target cells. After collecting the Au-Fe₃O₄ NP bioconjugate-cell complex on a magnet, the bioconjugate-cell complex was added to wells pre-coated with detector antibody then washed after incubation to remove unbound bioconjugate-cell complexes. TMB substrate was added to each well and the peroxidase-mimicking activity of any captured Au-Fe₃O₄ NP bioconjugate produced a blue coloured oxidation product in the presence of H₂O₂. The absorbance intensity of the oxidised TMB product was proportional to the amount of Au-Fe₃O₄ NP bioconjugate-cell complexes present after binding to the detector antibody. The more Au-Fe₃O₄ NP bioconjugate-cell complexes bound to the detector antibody, the greater the overall intensity of TMB oxidation signal produced. A schematic of the NPIDA is detailed in **Figure 4**. The NPIDA was then compared with conventional sandwich ELISA wherein plates were coated with capture antibody before adding target cells, followed by a secondary (detector) antibody, whose presence is then detected using an HRP conjugated anti-species antibody in a two-step consecutive process.

3.3 Discrete combinations of monoclonal and polyclonal antibodies enabled speciation of MTB and M. bovis

359 A total of 10 phage display derived recombinant binders were selected for investigation,
 360 produced as scFv-Fc antibodies, and initially tested by indirect ELISA. After titration using the
 361 MPT64 antigen as target and determination of cross reactivity, a single recombinant antibody
 362 (GSM237-G8) was chosen for further experiments (**Figure 5**).
 363 Approaches which combine immunomagnetic separation with sandwich ELISA format
 364 immunoassays are more sensitive than indirect ELISA as they facilitate enrichment of groups
 365 of target cells in samples of low concentration, such as the detection and enrichment of
 366 bacterial species in wastewater samples [51]. To select the optimal combination of antibodies
 367 for detection of each organism in the NPIDA, various pairs of target-binding capture and
 368 detection antibodies were screened by conventional sandwich ELISA (**Figure S2**). Each
 369 antibody combination was evaluated for optimal detection of MTB or *M. bovis* cells. In the
 370 conventional sandwich ELISA, the capture antibody selected for MTB was GSM237-G8,
 371 QUBMA-1 was selected for capture of *M. bovis* cells, and QUBPA-1 was selected as the
 372 detector antibody for both mycobacteria (**Figure S3**). In the NPIDA the detector antibody
 373 selected for MTB cell detection was GSM237-G8, QUBMA-1 was selected for detection of *M.*
 374 *bovis* cells, and QUBPA-1 was the capture antibody selected for both mycobacteria (**Figure**
 375 **S4**). Au-Fe₃O₄ NPs were functionalised with QUBPA-1 by DTT reduction. This method avoids
 376 modification of the antigen binding sites by reducing IgG antibody disulphide bonds within the
 377 antibody hinge region, enabling resultant thiol groups to anchor antibodies to the gold shell of
 378 the Au-Fe₃O₄ NPs [39-44, 52]. To confirm successful immobilisation of the antibody to the
 379 functionalised Au-Fe₃O₄ NPs and assess target specificity of the novel NPIDA, a cross-
 380 reactivity analysis was carried out by NPIDA and the results compared with conventional
 381 ELISA. In the NPIDA the NP bioconjugate was incubated overnight with MTB, *M. bovis* and
 382 *M. bovis* BCG-strain (NCTC5692) and two non-tuberculosis mycobacterial species, *M.*
 383 *kansasii* (NCTC10268) and *M. avium* subsp. *paratuberculosis* (MAP) (NCTC8578), whilst in
 384 parallel, GSM237-G8 antibody and QUBMA-1 were coated onto separate 96-well Nunc
 385 Maxisorp™ plates, and the assay carried out as detailed previously (2.7.1). The results
 386 showed that when GSM237-G8 was used as the detector antibody the mean OD₄₅₀ of Au-

387 Fe₃O₄ NP QUBPA-1 with MTB (1 ± 0.038) was significantly higher ($P < 0.001$) than the mean
388 value for *M. bovis* (0.33 ± 0.014), confirming that the antibody had been successfully
389 conjugated to the Au-Fe₃O₄ NP and the assay was more selective for MTB than *M. bovis*
390 (**Figure 6a**).

391 Other research groups have reported a decrease of binding affinity resulting from conjugation
392 of antibodies to labels such as fluorophores/ AuNPs and have indicated that such 'trade-offs'
393 may be necessary during attachment of binders [53]. However, in the present study, target
394 selectivity of the antibody was retained following conjugation to the Au-Fe₃O₄ NP by DTT
395 reduction, which has also been found by Ji *et al* [41]. A comparison between conventional
396 sandwich ELISA and Au-Fe₃O₄ NP QUBPA-1 bioconjugate with QUBMA-1 coated onto 96-
397 well plates indicated the bioconjugate had retained its selectivity for *M. bovis* and the mean
398 OD₄₅₀ of Au-Fe₃O₄ NP QUBPA-1 bioconjugate with *M. bovis* (1 ± 0.005) was found to be
399 significantly higher ($P < 0.001$) than the mean value for MTB (0.28 ± 0.022) (**Figure 6b**). The
400 novel NPIDA based assays for MTB and *M. bovis* can be run simultaneously using QUBPA-1
401 as the capture antibody and Nunc plates which are coated on one half with GSM237-G8 to
402 detect MTBC, and on the other half with QUBMA-1 to detect *M. bovis*. As such the one
403 immunoassay can be used to simultaneously detect and differentiate *M. bovis* from MTB.

404 The BD BACTEC™ MGIT™ is a liquid media system commonly used for cultivation of
405 mycobacteria. To determine the potential suitability of the novel NPIDA for detection of MTB
406 and *M. bovis* in culture media, and to compare the LOD_{50%} of each pathogen in buffer and
407 broth using both immunoassay formats, a tenfold dilution series of MTB and *M. bovis* ranging
408 from 1×10^5 CFU mL⁻¹ to 0 CFU mL⁻¹ was prepared in assay buffer and in MGIT media. The
409 NPIDAs and conventional ELISAs were carried out as detailed previously and the results for
410 each assay illustrated in **Table 1**. The results confirm that both the MTB and *M. bovis* ELISAs
411 and NPIDAs have comparable LOD_{50%} values, and therefore similar sensitivities, in both buffer
412 and BD BACTEC™ MGIT™ and indicate minimal matrix effects when the assays were
413 transferred from buffer into culture media. The novel NPIDA assay could be applied following

culture of samples and used to replace conventional Ziehl-Neelsen staining and subsequent molecular identification when a TB BACTEC™ MGIT™ culture indicates positive.

4. Conclusion

This study reports the synthesis of Au-Fe₃O₄ NPs by combining citrate capped AuNPs and co-precipitated Fe₃O₄ NPs. The physicochemical properties of the resultant iron oxide-gold composite NPs were characterised, and their magnetic separation capabilities and intrinsic peroxidase-like activity demonstrated. Functionalisation of the Au-Fe₃O₄ NPs with MTB and *M. bovis* selective antibodies led to the development of a NP-based immune-detection assay capable of detection and differentiating MTB and *M. bovis*. To the best of our knowledge this assay represents the first immune based diagnostic test capable of differentiating between MTB and *M. bovis*. The NPIDA demonstrated comparable levels of sensitivity and catalytic activity to conventional ELISA but enhanced pH and temperature stabilities compared with conventional HRP. The magnetic capability of the iron cores was exploited in sample preparation and the intrinsic peroxidase-mimicking ability of NPs negated the requirement for a time-consuming antibody incubation step required during conventional ELISA. The NPIDA is a low cost tool which can identify MTB, and speciate *M. bovis*, and therefore has the potential to more quickly direct patient treatment regimens thus improving the efficacy of treatments and reducing the emergence of TB drug-resistant phenotypes, particularly in high TB burden countries. The methodology described in this research should not be limited to the detection of MTBC but could be employed in other biosensing applications by combining Au-Fe₃O₄ NPs with alternative binders specific for metabolites or pathogens of biological interest. Future investigations will include extended cross reactivity studies and the application of the TB NIPDA directly with sputum samples.

Conflicts of interest

There are no conflicts to declare

Acknowledgements The authors B.G., C.C. and L.S. acknowledge funding from the PhD studentship support fund from the Department for the Economy for Northern Ireland (DfE). We would wish to thank Agri-Food and Biosciences Institute for Northern Ireland for providing access to one of the antibodies evaluated as part of this study.

Associated Supplementary Material

Recombinant antibody selection via phage display; DLS measurement of Fe₃O₄ NPs and Au-Fe₃O₄ NPs in water; Optimisation of antibody pair combinations with QUBPA-1 detection antibody; Schematic representation of the conventional sandwich ELISA with MTB and *M. bovis*; Schematic representation of the NPIDA with MTB and *M. bovis*.

References

- [1]. Y. Xia, Nanomaterials at work in biomedical research, Nat. Mater. 7(10) (2008) 758-760.
- [2]. J. Lou-Franco, B. Das, C. Elliott, C. Cao, Gold Nanozymes: From Concept to Biomedical Applications, Nanomicro Lett. 13(10) (2021).
- [3]. H.H. Yang, S.Q. Zhang, X.L. Chen, Z.X. Zhuang, J.G. Xu, X.R. Wang, Magnetite-Containing Spherical Silica Nanoparticles for Biocatalysis and Bioseparations, Anal. Chem. 76(5) (2004) 1316–1321.
- [4]. L. Gao, J. Zhuang, L. Nie, J. Zhang, Y. Zhang, N. Gu, T. Wang, J. Feng, D. Yang, S. Perrett, X. Yan, Intrinsic peroxidase-like activity of ferromagnetic nanoparticles, Nat. Nanotechnol. 2 (2007) 577–583.
- [5]. L. Félix, J. Coaquira, M. A. R. Martínez, G. F. Goya, J. Mantilla, M. H. Sousa, L. de los Santos Valladares, C. H. W. Barnes, P. C. Morais, Structural and magnetic properties of core-shell Au/Fe₃O₄ nanoparticles, Sci. Rep. 7 (2017) 41732.
- [6]. S.H. Sun, H. Zeng, Size-Controlled Synthesis of Magnetite Nanoparticles, J. Am. Chem. Soc. 124 (2002) 8204-8205.

468 [7]. J.L. Lyon, D.A. Fleming, M.B. Stone, P. Schiffer, M.E. Williams, Synthesis of Fe Oxide
 469 Core/Au Shell Nanoparticles by Iterative Hydroxylamine Seeding, *Nano Lett.* 4 (2004) 719–
 470 723.

471 [8]. World Health Organisation, 10 facts on Tuberculosis. (2020). Available at:
 472 <https://www.who.int/news-room/facts-in-pictures/detail/tuberculosisTB>. (Accessed:
 473 10/08/2021).

474 [9]. F. Olea-Popelka, A. Muwonge, A. Perera, A.S. Dean, E. Mumford, E. Erlacher-Vindel,
 475 S. Forcella, B.J. Silk, L. Ditiu, A. El Idrissi, M. Raviglione, O. Cosivi, P. LoBue, P.I. Fujiwara,
 476 Zoonotic tuberculosis in human beings caused by *Mycobacterium bovis*-a call for action,
 477 *Lancet Infect Dis.* 17(1) (2017) e21–e25.

478 [10]. D. Thierry, A. Brisson-Noël, V. Vincent-Lévy-Frébault, S. Nguyen, J.L. Guesdon, B.
 479 Gicquel, Characterization of a *Mycobacterium tuberculosis* insertion sequence, IS6110, and
 480 its application in diagnosis, *J. Clin. Microbiol.* 28(12) (1990) 2668–73.

481 [11]. M. Njire, Y. Tan, J. Mugweru, C. Wang, J. Guo, W. Yew, S. Tan, T. Zhang, Pyrazinamide
 482 resistance in *Mycobacterium tuberculosis*: Review and update, *Adv Med Sci.* 61(1) (2016) 63–
 483 71.

484 [12]. L.M. Parsons, R. Brosch, S.T. Cole, A. Somoskövi, A. Loder, G. Bretzel, D. Van
 485 Soolingen, Y.M. Hale, M. Salfinger, Rapid and simple approach for identification of
 486 *Mycobacterium tuberculosis* complex isolates by PCR-based genomic deletion analysis, *J.*
 487 *Clin. Microbiol.* 40(7) (2002) 2339–2345.

488 [13]. S. Singh, B. Dey, K.S. Sachdeva, S.K. Kabra, K.K. Chopra, V.K. Chaudhary, P.
 489 Sharma, V.M. Katoch, Challenges in Tuberculosis Diagnosis and Management:
 490 Recommendations of the Expert Panel, *J. Lab. Physicians.* 7(1) (2015) 1–3.

491 [14]. World Health Organisation, The End TB Strategy. (2020). Available at:
 492 <https://www.who.int/tb/strategy/en/> (Accessed: 25/08/2020).

493 [15]. G.E., Pfyffer, F., Wittwer, Incubation Time of Mycobacterial Cultures: How Long is Long
 494 Enough to Issue a Final Negative Report to the Clinician? *J. Clin. Microbiol.* 50(12) (2012)
 495 4188–4189.

496 [16]. A.J. Caulfield, N.L. Wengenack, Diagnosis of active tuberculosis disease: From
 497 microscopy to molecular techniques, J Clin Tuberc Other Mycobac Dis. 4 (2016) 33-43.

498 [17]. E. MacLean, M. Kohli, S.F. Weber, A. Suresh, S.G. Schumacher, C.M. Denking, M.
 499 Pai, Advances in Molecular Diagnosis of Tuberculosis, J. Clin. Microbiol. 58(10) (2020)
 500 e01582-19.

501 [18]. K. Weyer, F. Mirzayev, G.B. Migliori, W. Van Gemert, L. D'Ambrosio, M. Zignol, K. Floyd,
 502 R. Centis, D.M. Cirillo, E. Tortoli, C. Gilpin, J. de Dieu Iragena, D. Falzon, Mario Raviglione,
 503 Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert
 504 MTB/RIF, Eur. Respir. J. 42(1) (2013) 252–71.

505 [19]. V.G. Daftary, D.D. Banker, G.V. Daftary, ELISA test for tuberculosis, Indian J. Med. Sci.
 506 48(2) (1994) 39–42.

507 [20]. L. Sun, J. Xiao, Q. Miao, W. Feng, X. Wu, Q. Yin, Interferon gamma release assay in
 508 diagnosis of pediatric tuberculosis: a meta-analysis, FEMS Immunol Med Microbiol. 63(2)
 509 (2011) 165–73.

510 [21]. L.A.H. van Pinxteren, P. Ravn, E.M. Agger, J. Pollock, P. Andersen, Diagnosis of
 511 Tuberculosis Based on the Two Specific Antigens ESAT-6 and CFP10, Clin. diagn. lab.
 512 Immunol. 7(2) (2000) 155-160.

513 [22]. M. Kalra, G.K. Khuller, A. Grover, D. Behera, A. Wanchu, I. Verma, Utility of a
 514 combination of RD1 and RD2 antigens as a diagnostic marker for tuberculosis, Diagn.
 515 Microbiol. Infect. Dis. 66(2) (2010) 153–161.

516 [23]. N. Singh, V. Sreenivas, K.B. Gupta, Diagnosis of pulmonary and extrapulmonary
 517 tuberculosis based on detection of mycobacterial antigen 85B by immuno-PCR, Diagn.
 518 Microbiol. Infect. Dis. 83(4) (2015) 359–364.

519 [24]. T. Mustafa, H.G. Wiker, O. Mørkve, L. Sviland, Differential expression of mycobacterial
 520 antigen MPT64, apoptosis and inflammatory markers in multinucleated giant cells and
 521 epithelioid cells in granulomas caused by *Mycobacterium tuberculosis*, Virchows Arch. 452(4)
 522 (2008) 449–456.

523 [25]. J. Arora, G. Kumar, A.K. Verma, M. Bhalla, R. Sarin, V. Myneedu, Utility of MPT64
524 Antigen Detection for Rapid Confirmation of *Mycobacterium tuberculosis* Complex, J. Glob.
525 Infect. Dis. 7(2) (2015) 66–69.

526 [26]. H.M., Said, N., Ismail, A., Osman, C., Velsman, A.A. Hoosen, Evaluation of TBc
527 Identification Immunochromatographic Assay for Rapid Identification of *Mycobacterium*
528 *tuberculosis* Complex in Samples from Broth Cultures, J. Clin. Microbiol. 49(5) (2011) 1939-
529 1942.

530 [27]. K. Chikamatsu, A. Aono, H. Yamada, T. Sugamoto, T. Kato, Y. Kazumi, K. Tamai, H.
531 Yanagisawa, S. Mitarai, Comparative evaluation of three immunochromatographic
532 identification tests for culture confirmation of *Mycobacterium tuberculosis* complex, BMC
533 Infect. 14 (2014) 54.

534 [28]. P. Costa, A. Amaro, A. Botelho, J. Inácio, P.V. Baptista, Gold nanoprobe assay for the
535 identification of mycobacteria of the *Mycobacterium tuberculosis* complex, Clin. Microbiol.
536 Infect. 16(9) (2010) 1464–1469.

537 [29]. S. Prabhakar, A. Mishra, A. Singhal, V.M. Katoch, S.S. Thakral, J.S. Tyagi, H.K. Prasad,
538 Use of the *hupB* gene encoding a histone-like protein of *Mycobacterium tuberculosis* as a
539 target for detection and differentiation of *M. tuberculosis* and *M. bovis*, J. Clin. Microbiol. 42(6)
540 (2004) 2724–2732.

541 [30]. L.D. Stewart, N. Tort, P. Meakin, J.M. Argudo, R. Nzuma, N. Reid, I. Grant, Development
542 of a novel immunochromatographic lateral flow assay specific for *Mycobacterium bovis* cells
543 and its first application in combination with immunomagnetic separation to test badger faeces,
544 BMC Vet. Res. 13 (2017) 131.

545 [31]. L.D. Stewart, L. McCallan, J. McNair, A. McGoldrick, R. Morris, J.L. Moyon, L. De Juan
546 Ferré, B. Romero, E. Alonso, S.D.C. Parsons, P. Van Helden, F.R. Araújo, I.R. Grant,
547 Multilaboratory Evaluation of a Novel Lateral Flow Immunochromatographic Assay for
548 Confirming Isolation of *Mycobacterium bovis* from Veterinary Diagnostic Specimens. J. Clin.
549 Microbiol. 55(12) (2017) 3411–3425.

550 [32]. L.D. Stewart, J. McNair, L. McCallan, S. Thompson, L.A. Kulakov, I.R. Grant, Production
551 and evaluation of antibodies and phage display-derived peptide ligands for immunomagnetic
552 separation of *Mycobacterium bovis*, J. Clin. Microbiol. 50(5) (2012) 1598–1605.

553 [33]. G. Russo, V. Fühner, A. Frenzel, M. Hust, S. Dübel, Parallelized microscale expression
554 of soluble scFv. methods in molecular biology, Methods Mol Biol. 2025 (2019) 203-211.

555 [34]. J. Kügler, S. Wilke, D. Meier, F. Tomszak, A. Frenzel, T. Schirrmann, S. Dübel, H.
556 Garritsen, B. Hock, L. Toleikis, M. Schütte, M. Hust, Generation and analysis of the improved
557 human HAL9/10 antibody phage display libraries, BMC Biotechnol. 15(1) (2015) 10.

558 [35]. S. Mollova, I. Retter, M. Hust, S. Dübel, W. Müller, Analysis of single chain antibody
559 sequences using the VBASE2 Fab analysis tool, in: R. Kontermann & S. Dübel (Eds.),
560 Antibody Engineering, Springer Verlag., Berlin, (2010), pp. 3–10.

561 [36]. E.V. Wenzel, M. Bosnak, R. Tierney, M. Schubert, J. Brown, S. Dübel, A. Efstratiou, D.
562 Sesardic, P. Stickings, M. Hust, Human antibodies neutralizing diphtheria toxin *In vitro* and *In*
563 *vivo*, Sci. Rep. 10(1) (2020) 571.

564 [37]. V. Jäger, K. Büssow, A. Wagner, S. Weber, M. Hust, A. Frenzel, T. Schirrmann, High
565 level transient production of recombinant antibodies and antibody fusion proteins in HEK293
566 cells, BMC biotechnol. 13 (2013) 52.

567 [38]. T.T. Hien Pham, C. Cao, S.J. Sim, Application of citrate-stabilized gold-coated ferric
568 oxide composite nanoparticles for biological separations, J. Magn. Magn. 320(15) (2008)
569 2049-2055.

570 [39]. C. Cao, L.C. Gontard, L.L. Thuy Tram, A. Wolff, D.D. Bang, Dual enlargement of gold
571 nanoparticles: from mechanism to scanometric detection of pathogenic bacteria, Small. 7
572 (2011) 1701-1708.

573 [40]. G.T. Hermanson, Bioconjugate Techniques, 2nd Edition., Academic Press, Illinois
574 (USA), 2008.

575 [41]. T. Ji, M.C. Muenker, R.V. Papineni, J.W. Harder, D.L. Vizard, W.E. Mclaughlin,
576 Increased Sensitivity in Antigen Detection with Fluorescent Latex Nanosphere– IgG Antibody
577 Conjugates, Bioconjugate Chem. 21(3) (2010) 427-435.

578 [42]. E. Cortés, G. Corthey, P. Carro, C. Vericat, M.H. Fonticelli, G. Benítez, E. Pensa, A.A.
579 Rubert, R.C. Salvarezza, The Chemistry of the Sulfur–Gold Interface: In Search of a Unified
580 Model. *Acc. Chem. Res.* 45(8) (2012) 1183-1192.

581 [43]. AOAC International, Final Report and Executive Summaries from the AOAC
582 International Presidential Task Force on Best Practices in Microbiological Methodology.
583 (2018). Accessed: 29th June 2021
584 [[http://www.fda.gov/downloads/Food/FoodScienceResearch/ UCM088702.pdf](http://www.fda.gov/downloads/Food/FoodScienceResearch/UCM088702.pdf)].

585 [44]. K.R. Brown, D.G. Walter, M.J. Natan, Seeding of Colloidal Au Nanoparticle Solutions.
586 2. Improved Control of Particle Size and Shape, *Chem. Mater.* 12(2) (2000) 306-313.

587 [45]. A. Chingsungnoen, P. Chaiyachate, A. Dasri, Composite Fe₃O₄@Au Core-Shell
588 Nanoparticle: Tunable and Enhancement of Optical Absorption Property, *Orient. J. Chem.*
589 33(4) (2017).

590 [46]. M.R. Abedin, S. Umapathi, H. Mahendrakar, H.T. Laemthong, H. Coleman, D.
591 Muchangi, S. Santra, M. Nath, S. Barua, Polymer coated gold-ferric oxide superparamagnetic
592 nanoparticles for theranostic applications, *J. Nanobiotechnology*, 16(1) (2018) 80-92.

593 [47]. L. León Félix, B. Sanz, V. Sebastián, T.E. Torres, M.H. Sousa, J.A.H. Coquira, M.R.
594 Ibarra, G.F. Goya, Gold-decorated magnetic nanoparticles design for hyperthermia
595 applications and as a potential platform for their surface-functionalization, *Sci. Rep.* 9(1)
596 (2019) 4185-4196.

597 [48]. S. Singh, Nanomaterials Exhibiting Enzyme-Like Properties (Nanozymes): Current
598 Advances and Future Perspectives. *Front. Chem.* 7(46) (2019).

599 [49]. J. Liu, W. Zhang, H. Zhang, Z. Yang, T. Li, B. Wang, X. Huo, R. Wang, H. Chen, A
600 multifunctional nanoprobe based on Au–Fe₃O₄ nanoparticles for multimodal and ultrasensitive
601 detection of cancer cells, *ChemComm.* 49(43) (2013) 4938-4940.

602 [50]. Y. Tao, Y. Lin, J. Ren, X. Qu, A dual fluorometric and colorimetric sensor for dopamine
603 based on BSA-stabilized Au nanoclusters, *Biosens. Bioelectron.* 42 (2013) 41–46.

604 [51]. G. Pappert, M. Rieger, R. Niessner, Immunomagnetic nanoparticle-based sandwich
605 chemiluminescence-ELISA for the enrichment and quantification of *E. coli*, *Mikrochim Acta*
606 168 (2010) 1–8.

607 [52]. Á. Szabó, T. Szendi-Szatmári, L. Ujlaky-Nagy, I. Rádi, G. Vereb, J. Szöllősi, P. Nagy,
608 The effect of Fluorophore Conjugation on Antibody Affinity and the Photophysical Properties
609 of Dyes, *Biophys. J.* 114(3) (2018) 688–700.

610 [53]. Z. Dai, Z. Liu, B. Xiu, X. Yang, P. Zhao, X. Zhang, C. Duan, H. Que, H. Zhang, X. Feng,
611 A multiple-antigen detection assay for tuberculosis diagnosis based on broadly reactive
612 polyclonal antibodies, *Iran. J. Basic Med. Sci.* 20(4) (2017) 360–367.

613

614

615